INTRAVITREAL INJECTION DEVICE AND BEVACIZUMAB, RANIBUZIMAB, BEVACUZIMAB, AFLIBERCEPT OR TRIAMCINOLONE FOR USE IN A METHOD OF PREVENTING, TREATING OR DELAYING MACULAR DEGENERATION OR MACULAR DIABETIC EDEMA

摘要

The invention relates to an intravitreal injection device, comprising a syringe assembly, comprising a cylinder, a plunger and a needle, a tubular housing configured to receive the syringe assembly, and a positioning element arranged at a distal end of the tubular housing to position the injection device with respect to an eye to be treated. The syringe assembly is movable with respect to the tubular housing in axial direction of the tubular housing between a retracted position, in which the needle is arranged inside the tubular housing and an injection position in which the needle at least partially extends out of the tubular housing. The injection device comprises a first biasing element to bias with a first biasing force the syringe assembly to the retracted position, wherein exerting a pressure on the plunger results in movement of the syringe assembly from the retracted position to the injection position, and subsequently in an injection stroke, in which the plunger moves into the cylinder, and wherein the injection device is configured to automatically return, at the end of the injection stroke, at least the cylinder and needle of the syringe assembly to the retracted position independent from a pressure exerted on the plunger and/or a position of the plunger.